Abstract: The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

Abstract: A CO2 desorption system suitable for limited space in a complex sailing region comprises an exhaust boiler, a compact CO2 absorber, a compact CO2 lean-rich liquid heat exchanger, a compact CO2 desorber, a compact CO2 rich liquid preheating device, a compact CO2 rich liquid reboiling pre-desorption device and an intelligent control platform. Further, a global optimization control method for the CO2 desorption system suitable for limited space in a complex sailing region is further established based through a knowledge and data-driven exhaust extraction flow accurate-prediction model for a heat source of a CO2 rich liquid preheating device and a steam extraction flow accurate-prediction model for a heat source on an upper section of a CO2 rich liquid reboiling pre-desorption device to realize flexible control of operation parameters of the desorption system under different operating conditions of an engine.

Abstract: The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

Abstract: The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

Abstract: Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4?-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bound to the 4?-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5?-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4?-carbon of the sugar moiety or analog thereof.

Abstract: The invention relates generally to tRNA-based effector molecules (TREMs) comprising an asialoglycoprotein receptor (ASGPR) binding moiety, as well as compositions and methods relating thereto.

Abstract: The present invention relates to a method for carbon dioxide capture and concentration by partitioned multistage circulation based on mass transfer-reaction regulation. In the present invention, multiple means such as multistage circulating absorption, intelligent multi-factor regulation, pre-washing and cooling, inter-stage cooling, post-stage washing, slurry cleaning, cooling water waste heat utilization, small-particle-size and high-density spraying, external strengthening field such as a thermal field/ultrasonic field/electric field, and catalysis by composite catalyst are adopted, so that the target for low cost, low energy consumption, stability and high efficiency is realized. The secondary pollutants are effectively inhibited while carbon dioxide is efficiently captured; meanwhile, high-efficiency capture, low-energy desorption, and high-purity concentration of carbon dioxide are implemented.

Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

Abstract: Implementations of the present disclosure relate to methods, devices, and computer program products of extracting a feature for multimedia data that comprises a plurality of medium types. In a method, a first feature is determined for a first medium type in the plurality of medium types by masking a portion in a first medium object with the first medium type. A second feature is determined for a second medium type other than the first medium type in the plurality of medium types. The feature is generated for the multimedia data based on the first and second features. With these implementations, multiple medium types are considered in the feature extraction, and thus the feature may fully reflect various aspects of the multimedia data in an accurate way.

Abstract: The disclosure relates generally to uses of tRNA-based effector molecules having a non-naturally occurring modification.

Abstract: The disclosure relates generally to methods of modulating a production parameter of an RNA corresponding to, or polypeptide encoded by, a nucleic acid sequence comprising an endogenous ORF having a premature termination codon, comprising administering a tRNA-based effector molecule having a non-naturally occurring modification.

Abstract: Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4?-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bound to the 4?-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5?-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4?-carbon of the sugar moiety or analog thereof.

Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

Abstract: The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

Abstract: The present invention relates to a method for carbon dioxide capture and concentration by partitioned multistage circulation based on mass transfer-reaction regulation. In the present invention, multiple means such as multistage circulating absorption, intelligent multi-factor regulation, pre-washing and cooling, inter-stage cooling, post-stage washing, slurry cleaning, cooling water waste heat utilization, small-particle-size and high-density spraying, external strengthening field such as a thermal field/ultrasonic field/electric field, and catalysis by composite catalyst are adopted, so that the target for low cost, low energy consumption, stability and high efficiency is realized. The secondary pollutants are effectively inhibited while carbon dioxide is efficiently captured; meanwhile, high-efficiency capture, low-energy desorption, and high-purity concentration of carbon dioxide are implemented.

Abstract: A preparation method for a halogen-substituted compound is provided, where a piperazine derivative shown in formula I reacts with a halogenated acetyl halide derivative shown in formula VI to generate a halogen-substituted compound shown in formula II. The present invention further relates to a preparation method for preparing a pyrazole derivative by using a halogen-substituted compound, where a halogen-substituted compound shown in formula II reacts with methylhydrazine to close a pyrazole ring, to generate a halogen-substituted alkyl-1-methylpyrazole derivative shown in formula IV, or reacts with methylhydrazine benzaldehyde hydrazone to generate a hydrazone compound shown in formula III, which closes, under the action of an acid, a pyrazole ring to generate a halogen-substituted alkyl-1-methylpyrazole derivative shown in formula IV. The present invention further relates to a structure of an intermediate compound.

Abstract: Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4?-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The oligonucleotide of the disclosure comprises a 5?-terminal nucleotide represented by Formula III: wherein Ra, Rb, B, X2 and Y are as defined in the specification. The phosphate analogs are bound to the 4?-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5?-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4?-carbon of the sugar moiety or analog thereof.

Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.